SciNeuro
CompanyUnited States
SciNeuro develops one asset, in phase 2 (SNP318 in diabetic macular edema). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $53M
- 2
- Trials
- 0
- Signals
Pipeline
1Phase 2, Small molecule, diabetic macular edema, DME
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Funding rounds and grants1
- Signals1
- Similar companies6